EA200400796A1 - Композиции, содержащие поксвирус, и способ изготовления устойчивых композиций, содержащих поксвирус - Google Patents

Композиции, содержащие поксвирус, и способ изготовления устойчивых композиций, содержащих поксвирус

Info

Publication number
EA200400796A1
EA200400796A1 EA200400796A EA200400796A EA200400796A1 EA 200400796 A1 EA200400796 A1 EA 200400796A1 EA 200400796 A EA200400796 A EA 200400796A EA 200400796 A EA200400796 A EA 200400796A EA 200400796 A1 EA200400796 A1 EA 200400796A1
Authority
EA
Eurasian Patent Office
Prior art keywords
poxvirus
compositions containing
composition
containing poxvirus
lyophilized
Prior art date
Application number
EA200400796A
Other languages
English (en)
Other versions
EA006880B1 (ru
Inventor
Пол Хаули
Карл Хеллер
Ингмар Рете
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200400796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA200400796A1 publication Critical patent/EA200400796A1/ru
Publication of EA006880B1 publication Critical patent/EA006880B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к композиции, в частности водной композиции, включающей (i) поксвирус одного из родов Orthopoxvirus, Avipoxvirus, Parapoxvirus, Capripoxvirus и Suipoxvirus, (ii) дисахарид, (iii) фармацевтически приемлемый полимер и, необязательно, (iv) буфер. Водная композиция особенно подходит для способов лиофилизации, приводящих к изготовлению устойчивой, лиофилизированной, содержащей поксвирус композиции. Изобретение, кроме того, касается способа изготовления лиофилизированной, содержащей поксвирус композиции и полученного таким образом продукта.Отчет о международном поиске был опубликован 2004.03.04.
EA200400796A 2001-12-10 2002-11-28 Композиции, содержащие поксвирус, и способ изготовления устойчивых композиций, содержащих поксвирус EA006880B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101831 2001-12-10
PCT/EP2002/013434 WO2003053463A2 (en) 2001-12-10 2002-11-28 Poxvirus-containing compositions and process for their preparation

Publications (2)

Publication Number Publication Date
EA200400796A1 true EA200400796A1 (ru) 2004-12-30
EA006880B1 EA006880B1 (ru) 2006-04-28

Family

ID=8160885

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400796A EA006880B1 (ru) 2001-12-10 2002-11-28 Композиции, содержащие поксвирус, и способ изготовления устойчивых композиций, содержащих поксвирус

Country Status (22)

Country Link
US (1) US7094412B2 (ru)
EP (1) EP1418942B1 (ru)
JP (1) JP4439263B2 (ru)
KR (1) KR20040074067A (ru)
CN (1) CN1296096C (ru)
AT (1) ATE300954T1 (ru)
AU (1) AU2002361962A1 (ru)
BR (1) BR0214822A (ru)
CA (1) CA2467365C (ru)
DE (1) DE60205388T2 (ru)
DK (1) DK1418942T3 (ru)
EA (1) EA006880B1 (ru)
ES (1) ES2247414T3 (ru)
HK (1) HK1071295A1 (ru)
HU (1) HUP0402179A3 (ru)
IL (2) IL161590A0 (ru)
MX (1) MXPA04005577A (ru)
NO (1) NO20042958L (ru)
NZ (1) NZ533302A (ru)
PL (1) PL213326B1 (ru)
UA (1) UA78738C2 (ru)
WO (1) WO2003053463A2 (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PL215169B1 (pl) 2002-09-05 2013-10-31 Bavarian Nordic As Sposób amplifikacji wirusów, kompozycja zawierajaca pokswirusa uzyskanego tym sposobem oraz jego zastosowanie do otrzymywania szczepionki
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
JP5138601B2 (ja) * 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
NZ578960A (en) 2007-05-14 2012-11-30 Bavarian Nordic As Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
DK2148923T3 (da) * 2007-05-18 2012-12-03 Medimmune Llc Konservering af biologisk aktive materialer med frysetørret skum
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
CA2767924A1 (en) 2009-10-08 2011-04-14 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
WO2011145013A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. Parapoxvirus vectors containing rabies virus antigen
CA2804890A1 (en) 2010-07-20 2012-01-26 Ah Usa 42 Llc Parapoxvirus vectors
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
US10357555B2 (en) 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
WO2016087457A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US20190330655A1 (en) 2016-12-28 2019-10-31 Transgene Sa Oncolytic viruses and therapeutic molecules
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624845A1 (en) * 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
MA49397A (fr) 2017-06-15 2020-04-22 Bavarian Nordic As Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP3762020A1 (en) 2018-03-07 2021-01-13 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JP7437385B2 (ja) 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
JPWO2020090871A1 (ja) 2018-10-30 2021-10-07 国立大学法人 東京大学 がん治療のための腫瘍溶解性ウイルス
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
WO2020136235A1 (en) 2018-12-28 2020-07-02 Transgene Sa M2-defective poxvirus
EP4117722A1 (en) 2020-03-12 2023-01-18 Bavarian Nordic A/S Compositions improving poxvirus stability
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
TW202413636A (zh) 2022-08-18 2024-04-01 法商傳斯堅公司 嵌合痘病毒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (ru)
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
FR7773M (ru) * 1968-06-14 1970-03-23
US3577526A (en) * 1969-06-13 1971-05-04 Merieux Inst Stabilized smallpox vaccine
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
CA2158935A1 (en) 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
US6869793B2 (en) * 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors

Also Published As

Publication number Publication date
NZ533302A (en) 2005-11-25
NO20042958L (no) 2004-07-09
HUP0402179A2 (hu) 2005-01-28
CN1602205A (zh) 2005-03-30
EP1418942A2 (en) 2004-05-19
WO2003053463A3 (en) 2004-03-04
ES2247414T3 (es) 2006-03-01
WO2003053463A2 (en) 2003-07-03
EP1418942B1 (en) 2005-08-03
MXPA04005577A (es) 2005-04-19
CA2467365C (en) 2012-11-20
US7094412B2 (en) 2006-08-22
EA006880B1 (ru) 2006-04-28
PL213326B1 (pl) 2013-02-28
BR0214822A (pt) 2004-12-14
CA2467365A1 (en) 2003-07-03
IL161590A0 (en) 2004-09-27
DE60205388T2 (de) 2006-03-30
DE60205388D1 (de) 2005-09-08
US20050019349A1 (en) 2005-01-27
PL369954A1 (en) 2005-05-02
ATE300954T1 (de) 2005-08-15
UA78738C2 (en) 2007-04-25
JP2005513109A (ja) 2005-05-12
AU2002361962A1 (en) 2003-07-09
JP4439263B2 (ja) 2010-03-24
HUP0402179A3 (en) 2012-09-28
HK1071295A1 (en) 2005-07-15
DK1418942T3 (da) 2005-11-28
IL161590A (en) 2009-06-15
CN1296096C (zh) 2007-01-24
KR20040074067A (ko) 2004-08-21

Similar Documents

Publication Publication Date Title
EA200400796A1 (ru) Композиции, содержащие поксвирус, и способ изготовления устойчивых композиций, содержащих поксвирус
DK1766003T3 (da) Thrombinpræparater
IL159724A0 (en) A nitrogen oxide generating composition for treatment of nail infections
MXPA01006917A (es) Composicion topica que comprende n-acetilaldosaminas o acidos n-acetilaminos.
ATE397936T1 (de) Therapeutische verfahren unter verwendung von pflanzlichen zusammensetzungen
NO20026044L (no) Behandling av humant papillomavirus
BR0100135A (pt) Composição e processo de lavagem de matériais queratìnicas e utilização de pelo menos um éster de ácido c8-c30 de sorbitano
BR0114785A (pt) Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença.
WO2002038105A3 (en) Novel polyamine analog-amino acid conjugates useful as anticancer agents
BR9709829A (pt) Formas de dosagem biconvexas de rápida desintegração
BR9915988A (pt) Vacina para peptidase c5a estreptocócica
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
GT200100126A (es) Preparaciones de retardo de antibioticos de quinolona y procedimiento para su fabricacion.
WO2021154812A8 (en) Coronavirus vaccine formulations
WO2003016544A1 (fr) Procede d'elaboration d'acide 1,4-dihydroxy-2-naphtoique
WO2004080415A3 (en) Gel composition and method for treatment of vaginal infections
TR200002078T2 (tr) Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar.
ATE305921T1 (de) Neue analoga von 16-hydroxyeicosatetraensäure
BR0203517A (pt) Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2002048675A3 (en) Improved compositions and methods for producing antibodies to low molecular weight analytes
MX2018006870A (es) Uso de citrato de sodio como agente removedor de barrillo dentinario.
AR122262A1 (es) Subunidad s1 modificada de la proteína de espícula de coronavirus
AR027791A1 (es) Proteinas de fusion con hemolisina, produccion y uso de las mismas
WO2001051080A3 (en) Methods and compositions for obtaining disease protection for animals

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU